Qualigen Therapeutics Inc.

About Qualigen Therapeutics Inc.

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing innovative medical products and treatments for adult and pediatric cancer, particularly in areas of high unmet medical need. They are committed to combining their development and commercialization capabilities with major cancer research to deliver new therapeutics for patients with rare cancers.

Products & Services

QN-302:An investigational oncology program in development for cancer treatment.

Specialties

Cancer Therapeutics Oncology Drug Development Rare Cancer Treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: PIPE T: - FT: PIPE	A: 41000000 MR: - FA: $41 million FAN: 41000000	D: 2025-09-30 FD: 2025-09-30	4 investors
2	RT: Strategic Investment T: - FT: Strategic Investment	A: 41000000 MR: - FA: $41 million FAN: 41000000	D: 2025-09-30 FD: 2025-09-30	3 investors
3	RT: PIPE (Private Investment in Public Equity) T: - FT: PIPE (Private Investment in Public Equity)	A: 41000000 MR: - FA: $41 million FAN: 41000000	D: 2025-09-19 FD: 2025-09-19	3 investors
4	RT: Series A-3 Private Placement T: - FT: Series A-3 Private Placement	A: 4500000 MR: - FA: $4.5 million FAN: 4500000	D: 2025-07-28 FD: 2025-07-28	-
5	RT: Private Placement T: - FT: Private Placement	A: 5100000 MR: - FA: 5.1 million FAN: 5100000	D: 2024-11-25 FD: 2024-11-25	-
6	RT: Private Placement T: - FT: Private Placement	A: 4500000 MR: - FA: 4.5 million FAN: 4500000	D: 2024-11-19 FD: 2024-11-19	1 investors
7	RT: Public Offering T: - FT: Public Offering	A: 3470000 MR: - FA: 3.47 million FAN: 3470000	D: 2024-09-06 FD: 2024-09-06	-
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3460000 MR: - FA: $3.46 million FAN: 3460000	D: 2024-09-06 FD: 2024-09-06	1 investors
9	RT: Public Offering T: - FT: Public Offering	A: 3460000 MR: - FA: approximately $3.46 million FAN: 3460000	D: 2024-09-05 FD: 2024-09-05	1 investors

PIPE Latest

2025-09-30

$41.0M

4 investors (Pro only)

Strategic Investment 2025-09-30

$41.0M

PIPE (Private Investment in Public Equity) 2025-09-19

$41.0M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

R. Campbell Becher

President

K

Kevin A. Richardson II

Interim CEO/CFO

M

Michael S. Poirier

Chairman, President and Chief Executive Officer

C

Christopher L. Lotz

Vice President, Chief Financial Officer, Corporate Secretary

T

Tariq Arshad MD, MBA

Senior Vice President, Chief Medical Officer

B

Benedict M. Abugan

Vice President, Head of Diagnostics and Corporate Communications

View 16 more team members with Pro

Unlock Full Team Directory

Recent News